Set, Setting & Session Safety

The dosing day is the acute-risk window — treat it that way

Everything upstream of dosing day — screening, medication reconciliation, cardiac clearance, informed consent — exists to reduce risk before any medicine is given. But the dosing session itself is where several rare, serious, and fast-moving risks actually live: cardiac arrhythmia, serotonin toxicity, hyperthermia, acute psychiatric decompensation, and dissociation intense enough to be mistaken for either of the first two. This module assumes the Readiness Standard's Phase 3 Clear-to-Treat handoff has already happened and been signed by the clinician-of-record Established. Your job on dosing day is monitoring, presence, and knowing exactly when "expected and difficult" becomes "a medical emergency."

This standard, and this module, certify the preparation and monitoring process — not any substance's safety or efficacy. Ibogaine, MDMA, psilocybin, LSD, and DMT remain Schedule I under US federal law; none of them, nor MDMA, is FDA-approved for any indication. Only esketamine (Spravato) carries FDA approval, for treatment-resistant depression, delivered as a nasal spray; generic ketamine is a Schedule III agent used off-label as a dissociative anesthetic/adjunct.

Vital-sign monitoring over time: what to track, how often

The Common Outcome Protocol's day-of dataset requires vital signs over time and a graded adverse-event log for every modality — not a single pre/post reading Established. Parameters and frequency track each medicine's signature risk:

• Ibogaine — continuous cardiac monitoring (telemetry/ECG) for the full dosing period and well beyond, because the arrhythmia risk is not confined to the visible peak. Ibogaine and its active metabolite noribogaine block the cardiac hERG potassium channel, prolonging the QT interval, and can trigger ventricular arrhythmia including torsades de pointes at ordinary therapeutic doses in people with no prior heart disease Established. Noribogaine's long elimination half-life means this risk can persist for days, not hours — monitoring duration should reflect that, not just the acute session.
• MDMA — blood pressure, heart rate, and core temperature at regular intervals throughout, with closer attention during the roughly 60–120 minute window of peak effect when serotonergic and thermogenic load is highest Established.
• Ketamine — blood pressure and heart rate (a transient rise is expected and usually self-limited), plus a structured dissociation check rather than a single "are you okay" Established.
• Psilocybin/LSD — blood pressure and heart rate at intervals; medical toxicity in controlled settings is generally low, so the greater monitoring burden here is psychological, not cardiac Established.

Dissociation is expected with some medicines — measure it, don't just eyeball it

Dissociation (detachment from body, environment, or self) is a normal, dose-dependent, usually mild-to-moderate effect of ketamine, and can occur with other modalities. The field's validated tool for tracking it is the Clinician-Administered Dissociative States Scale (CADSS), a clinician-rated instrument now standard for monitoring ketamine-induced dissociation in clinical and research settings; a validated 6-item short form (CADSS-6) exists specifically for repeat monitoring across infusions Established. The Common Outcome Protocol lists CADSS as a validated day-of measure alongside the Emotional Breakthrough Inventory Established.

• Expected: perceptual distortion, altered sense of time, feeling "outside the body," derealization — this is the mechanism at work, especially with ketamine, not a malfunction.
• Watch closer: dissociation severe enough that the patient cannot respond to your voice, cannot protect their airway, or occurs alongside falling blood pressure or a new arrhythmia — now you are evaluating a medical event, not a psychological one.
• Document it structurally: rating dissociation on CADSS or CADSS-6 at intervals turns "the session was intense" into comparable, registry-grade data, and gives you an objective marker of whether severity is escalating or resolving.

The facilitator's stance: calm, present, non-directive

Across published psilocybin- and MDMA-assisted therapy protocols, the facilitator's role during dosing is deliberately non-directive: minimal talking, no steering the content of the experience, a supportive rather than interpretive presence. This is a procedural convention drawn from the field's therapy manuals, not a proven cause of better outcomes — the honest evidence here is correlational. In a controlled psilocybin-assisted therapy trial for major depressive disorder, stronger therapeutic alliance measured before dosing predicted better acute-experience ratings and lower depression scores at 4 weeks through 12 months, but alliance and a non-directive style are associated with outcomes, not demonstrated to cause them Plausible.

• Do: stay physically present, speak rarely and briefly, and let the patient's process unfold without interpreting it for them.
• Don't: offer analysis, ask leading questions about content ("what does that mean to you"), or fill silence out of your own discomfort — the dosing session is not the moment for insight-oriented work.
• Exception, always: the non-directive stance stops the instant there is a safety concern. Calm demeanor is a technique for the psychological work, never a reason to delay a medical or psychiatric intervention.

Cardiac emergency preparedness — highest stakes: ibogaine

Ibogaine's cardiac risk is the reason continuous monitoring and emergency readiness are non-negotiable for this modality specifically, not optional add-ons Established.

If a new arrhythmia, syncope, chest pain, or a QTc that has meaningfully lengthened from baseline appears, that is a medical emergency, not a difficult moment in the experience. Stop, treat per ACLS/institutional protocol, and escalate — do not attempt to manage a cardiac event with reassurance and a non-directive stance.

Recognizing serotonin syndrome — highest stakes: MDMA

MDMA is a potent serotonin-releasing agent. Combined with another serotonergic drug (SSRIs, SNRIs, MAOIs, and some analgesics used in acute care) it can precipitate serotonin syndrome, diagnosed clinically with the Hunter Serotonin Toxicity Criteria: spontaneous or inducible clonus, agitation, tremor with hyperreflexia, hypertonia with temperature above 38°C, or ocular clonus, in the setting of a recent serotonergic exposure Established. This is why the Common Core's medication reconciliation and a supervised taper of serotonergic medications before an MDMA session — done by the prescriber, never by education alone — is a hard gate, not a suggestion.

• Recognize early: agitation, tremor, and clonus (especially inducible ankle clonus on exam) are the findings that separate this from an emotionally intense session.
• First-line response: stop or avoid additional serotonergic agents, provide supportive care (cooling, IV fluids), and use benzodiazepines for agitation and to reduce autonomic/neuromuscular activity; escalate urgently for temperature above 41°C, rigidity, or hemodynamic instability.
• Don't conflate with hyperthermia alone: MDMA can independently cause hyperthermia and hyponatremia (from overhydration or an SIADH-like effect) without full serotonin syndrome — both need active temperature and fluid management regardless of which is present.

Psychiatric emergencies and adverse-event escalation

Most "difficult" moments in a dosing session — fear, grief, confusion, transient paranoia — fall in the expected range and are managed with the non-directive supportive stance above, not medication. A true psychiatric emergency is different: acute psychosis, dissociation with loss of situational awareness that does not resolve with grounding, or any new expression of self-harm intent. The latter requires immediate, non-negotiable escalation regardless of how "into the experience" the setting is meant to be — the Common Outcome Protocol treats a positive suicide-risk screen as an immediate-escalation trigger, never a data point to note and revisit later Established.

• Before escalating to emergency services, know in advance: nearest emergency department, on-call physician/psychiatrist contact, and your facility's own crisis protocol — decided before dosing day, not during it.
• Veterans Crisis Line for any patient expressing suicidal ideation: 988, press 1 — have this posted, not just known.
• A calm facilitator and a functioning emergency plan are not in tension: the calm is for the patient, the plan is for you, and it should already be staged before the first dose is given.

Day-of readiness: the checklist before the first dose